Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Differences in clinical characteristics and outcomes between men and women with idiopathic pulmonary fibrosis: a multicenter retrospective cohort study.

Zaman T, Moua T, Vittinghoff E, Ryu JH, Collard HR, Lee JS.

Chest. 2020 Feb 18. pii: S0012-3692(20)30281-6. doi: 10.1016/j.chest.2020.02.009. [Epub ahead of print]

PMID:
32084394
2.

Acute exacerbation of idiopathic pulmonary fibrosis: International survey and call for harmonisation.

Kreuter M, Polke M, Walsh SLF, Krisam J, Collard HR, Chaudhuri N, Avdeev S, Behr J, Calligaro G, Corte T, Flaherty K, Funke-Chambour M, Kolb M, Kondoh Y, Maher TM, Molina MM, Morais A, Moor CC, Morisset J, Pereira C, Quadrelli S, Selman M, Tzouvelekis A, Valenzuela C, Vancheri C, Vicens-Zygmunt V, Wälscher J, Wuyts W, Wijsenbeek M, Cottin V, Bendstrup E.

Eur Respir J. 2020 Feb 14. pii: 1901760. doi: 10.1183/13993003.01760-2019. [Epub ahead of print]

PMID:
32060068
3.

A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis.

Barnes H, Morisset J, Molyneaux P, Westall G, Glaspole I, Collard HR; CHP Exposure Assessment Collaborators.

Chest. 2020 Jan 17. pii: S0012-3692(20)30022-2. doi: 10.1016/j.chest.2019.12.018. [Epub ahead of print]

PMID:
31958445
4.

Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF.

Farrand E, Vittinghoff E, Ley B, Butte AJ, Collard HR.

Respirology. 2019 Dec 17. doi: 10.1111/resp.13753. [Epub ahead of print]

PMID:
31846126
5.

Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes.

Casanova N, Zhou T, Gonzalez-Garay ML, Rosas IO, Goldberg HJ, Ryter SW, Collard HR, El-Chemaly S, Flaherty KR, Hunninghake GM, Lasky JA, Lederer DJ, Machado RF, Martinez FJ, Noth I, Raghu G, Choi AMK, Garcia JGN.

Sci Rep. 2019 Oct 15;9(1):14802. doi: 10.1038/s41598-019-50585-3.

6.

Which Biopsy to Diagnose Interstitial Lung Disease? A Call for Evidence and Unity.

Richeldi L, Cottin V, Brown KK, Flaherty KR, Johannson KA, Travis WD, Collard HR.

Am J Respir Crit Care Med. 2019 Oct 1;200(7):941-942. doi: 10.1164/rccm.201905-0932LE. No abstract available.

7.

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.

Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, Corte TJ, Keogh AM, Leuchte H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Boateng F, Wells AU.

Lancet Respir Med. 2019 Sep;7(9):780-790. doi: 10.1016/S2213-2600(19)30250-4. Epub 2019 Aug 12.

PMID:
31416769
8.

Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in North American Patients With Idiopathic Pulmonary Fibrosis.

Liu GY, Ventura IB, Achtar-Zadeh N, Elicker BM, Jones KD, Wolters PJ, Collard HR, Adegunsoye A, Strek ME, Ley B.

Chest. 2019 Oct;156(4):715-723. doi: 10.1016/j.chest.2019.05.014. Epub 2019 Jun 7.

PMID:
31181198
9.

Reply to: Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity!

Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C.

Eur Respir J. 2019 May 9;53(5). pii: 1900615. doi: 10.1183/13993003.00615-2019. Print 2019 May. No abstract available.

PMID:
31072878
10.

Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.

Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Kim DS, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundy JS, O'Riordan T, Strek ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Worboys AM, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):199-208. doi: 10.1164/rccm.201810-1891OC.

11.

Significance of bronchiolocentric fibrosis in patients with histopathological usual interstitial pneumonia.

Tanizawa K, Ley B, Vittinghoff E, Elicker BM, Henry TS, Wolters PJ, Brownell R, Liu S, Collard HR, Jones KD.

Histopathology. 2019 Jun;74(7):1088-1097. doi: 10.1111/his.13840. Epub 2019 Apr 25.

PMID:
30742318
12.

The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study.

Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C.

Eur Respir J. 2019 Mar 7;53(3). pii: 1801587. doi: 10.1183/13993003.01587-2018. Print 2019 Mar.

PMID:
30578385
13.

Closing the Evidence Gap in Interstitial Lung Disease. The Promise of Real-World Data.

Farrand E, Anstrom KJ, Bernard G, Butte AJ, Iribarren C, Ley B, Martinez FJ, Collard HR.

Am J Respir Crit Care Med. 2019 May 1;199(9):1061-1065. doi: 10.1164/rccm.201807-1209PP. No abstract available.

PMID:
30452876
14.

Response.

Johannson KA, Vittinghoff E, Morisset J, Wolters PJ, Noth EM, Balmes JR, Collard HR.

Chest. 2018 Sep;154(3):727-728. doi: 10.1016/j.chest.2018.05.042. No abstract available.

PMID:
30195362
15.

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST.

PMID:
30168753
16.

Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial.

Raghu G, Pellegrini CA, Yow E, Flaherty KR, Meyer K, Noth I, Scholand MB, Cello J, Ho LA, Pipavath S, Lee JS, Lin J, Maloney J, Martinez FJ, Morrow E, Patti MG, Rogers S, Wolters PJ, Yates R, Anstrom KJ, Collard HR.

Lancet Respir Med. 2018 Sep;6(9):707-714. doi: 10.1016/S2213-2600(18)30301-1. Epub 2018 Aug 9.

PMID:
30100404
17.

Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials.

Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR.

Lancet Respir Med. 2018 Aug;6(8):615-626. doi: 10.1016/S2213-2600(18)30185-1. Epub 2018 Jun 29.

PMID:
30072107
18.

Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study.

Dressen A, Abbas AR, Cabanski C, Reeder J, Ramalingam TR, Neighbors M, Bhangale TR, Brauer MJ, Hunkapiller J, Reeder J, Mukhyala K, Cuenco K, Tom J, Cowgill A, Vogel J, Forrest WF, Collard HR, Wolters PJ, Kropski JA, Lancaster LH, Blackwell TS, Arron JR, Yaspan BL.

Lancet Respir Med. 2018 Aug;6(8):603-614. doi: 10.1016/S2213-2600(18)30135-8. Epub 2018 Jun 18.

19.

Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis.

Guler SA, Ellison K, Algamdi M, Collard HR, Ryerson CJ.

Ann Am Thorac Soc. 2018 Jul;15(7):854-863. doi: 10.1513/AnnalsATS.201801-067OC.

PMID:
29779392
20.

Burden, resilience and coping in caregivers of patients with interstitial lung disease.

Shah RJ, Collard HR, Morisset J.

Heart Lung. 2018 May - Jun;47(3):264-268. doi: 10.1016/j.hrtlng.2018.03.004. Epub 2018 Apr 4.

21.

Air Pollution Exposure Is Associated With Lower Lung Function, but Not Changes in Lung Function, in Patients With Idiopathic Pulmonary Fibrosis.

Johannson KA, Vittinghoff E, Morisset J, Wolters PJ, Noth EM, Balmes JR, Collard HR.

Chest. 2018 Jul;154(1):119-125. doi: 10.1016/j.chest.2018.01.015. Epub 2018 Feb 7.

22.

Reply to Moodley: A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease.

Ryerson CJ, Walsh SLF, Collard HR; all authors.

Am J Respir Crit Care Med. 2018 May 15;197(10):1366-1367. doi: 10.1164/rccm.201712-2515LE. No abstract available.

PMID:
29342368
23.

Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey.

Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, Ley B; HP Delphi Collaborators.

Am J Respir Crit Care Med. 2018 Apr 15;197(8):1036-1044. doi: 10.1164/rccm.201710-1986OC. Epub 2017 Nov 27.

24.

A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis.

Rosas IO, Goldberg HJ, Collard HR, El-Chemaly S, Flaherty K, Hunninghake GM, Lasky JA, Lederer DJ, Machado R, Martinez FJ, Maurer R, Teller D, Noth I, Peters E, Raghu G, Garcia JGN, Choi AMK.

Chest. 2018 Jan;153(1):94-104. doi: 10.1016/j.chest.2017.09.052. Epub 2017 Oct 31.

25.

Idiopathic pulmonary fibrosis.

Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, Swigris JJ, Taniguchi H, Wells AU.

Nat Rev Dis Primers. 2017 Oct 20;3:17074. doi: 10.1038/nrdp.2017.74. Review.

PMID:
29052582
26.

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.

Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, Devaraj A, Inoue Y, Le Maulf F, Richeldi L, Schmidt H, Walsh S, Mezzanotte W, Schlenker-Herceg R.

BMJ Open Respir Res. 2017 Sep 17;4(1):e000212. doi: 10.1136/bmjresp-2017-000212. eCollection 2017.

27.

COUNTERPOINT: Should BAL Be Routinely Performed in the Diagnostic Evaluation of Idiopathic Pulmonary Fibrosis? No.

Mooney JJ, Collard HR.

Chest. 2017 Nov;152(5):919-922. doi: 10.1016/j.chest.2017.08.1172. Epub 2017 Sep 21. No abstract available.

PMID:
28943280
28.

Rebuttal From Drs Mooney and Collard.

Mooney JJ, Collard HR.

Chest. 2017 Nov;152(5):923-924. doi: 10.1016/j.chest.2017.08.1175. Epub 2017 Sep 21. No abstract available.

PMID:
28943278
29.

Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management.

Oldham JM, Collard HR.

Front Med (Lausanne). 2017 Aug 2;4:123. doi: 10.3389/fmed.2017.00123. eCollection 2017. Review.

30.

Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis.

Johannson KA, Vittinghoff E, Morisset J, Lee JS, Balmes JR, Collard HR.

Eur Respir J. 2017 Jul 5;50(1). pii: 1602406. doi: 10.1183/13993003.02406-2016. Print 2017 Jul.

31.

Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis.

Cottin V, Hansell DM, Sverzellati N, Weycker D, Antoniou KM, Atwood M, Oster G, Kirchgaessler KU, Collard HR, Wells AU.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1162-1171. doi: 10.1164/rccm.201612-2492OC.

PMID:
28657784
32.

Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.

Morisset J, Vittinghoff E, Elicker BM, Hu X, Le S, Ryu JH, Jones KD, Haemel A, Golden JA, Boin F, Ley B, Wolters PJ, King TE Jr, Collard HR, Lee JS.

Chest. 2017 Nov;152(5):999-1007. doi: 10.1016/j.chest.2017.06.009. Epub 2017 Jun 16.

33.

Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis.

Collard HR, Richeldi L, Kim DS, Taniguchi H, Tschoepe I, Luisetti M, Roman J, Tino G, Schlenker-Herceg R, Hallmann C, du Bois RM.

Eur Respir J. 2017 May 19;49(5). pii: 1601339. doi: 10.1183/13993003.01339-2016. Print 2017 May.

34.

The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.

Morisset J, Vittinghoff E, Lee BY, Tonelli R, Hu X, Elicker BM, Ryu JH, Jones KD, Cerri S, Manfredi A, Sebastiani M, Gross AJ, Ley B, Wolters PJ, King TE Jr, Kim DS, Collard HR, Lee JS.

Respir Med. 2017 Jun;127:51-56. doi: 10.1016/j.rmed.2017.04.012. Epub 2017 Apr 22.

35.

Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease.

Natalini JG, Swigris JJ, Morisset J, Elicker BM, Jones KD, Fischer A, Collard HR, Lee JS.

Respir Med. 2017 Jun;127:1-6. doi: 10.1016/j.rmed.2017.04.002. Epub 2017 Apr 5.

36.

Giants in Chest Medicine: Talmadge E. King Jr, MD, FCCP.

Collard HR.

Chest. 2017 May;151(5):960-961. doi: 10.1016/j.chest.2016.11.060. No abstract available.

PMID:
28483131
37.

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.

Ley B, Swigris J, Day BM, Stauffer JL, Raimundo K, Chou W, Collard HR.

Am J Respir Crit Care Med. 2017 Sep 15;196(6):756-761. doi: 10.1164/rccm.201701-0091OC.

38.

A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective.

Ryerson CJ, Corte TJ, Lee JS, Richeldi L, Walsh SLF, Myers JL, Behr J, Cottin V, Danoff SK, Flaherty KR, Lederer DJ, Lynch DA, Martinez FJ, Raghu G, Travis WD, Udwadia Z, Wells AU, Collard HR.

Am J Respir Crit Care Med. 2017 Nov 15;196(10):1249-1254. doi: 10.1164/rccm.201702-0400PP. No abstract available.

39.

Idiopathic pulmonary fibrosis.

Richeldi L, Collard HR, Jones MG.

Lancet. 2017 May 13;389(10082):1941-1952. doi: 10.1016/S0140-6736(17)30866-8. Epub 2017 Mar 30. Review.

PMID:
28365056
40.

Code-based Diagnostic Algorithms for Idiopathic Pulmonary Fibrosis. Case Validation and Improvement.

Ley B, Urbania T, Husson G, Vittinghoff E, Brush DR, Eisner MD, Iribarren C, Collard HR.

Ann Am Thorac Soc. 2017 Jun;14(6):880-887. doi: 10.1513/AnnalsATS.201610-764OC.

41.

Improving Survival in Idiopathic Pulmonary Fibrosis: The Race Has Just Begun.

Collard HR.

Chest. 2017 Mar;151(3):527-528. doi: 10.1016/j.chest.2017.01.007. No abstract available.

PMID:
28279270
42.

CXCL14 is a candidate biomarker for Hedgehog signalling in idiopathic pulmonary fibrosis.

Jia G, Chandriani S, Abbas AR, DePianto DJ, N'Diaye EN, Yaylaoglu MB, Moore HM, Peng I, DeVoss J, Collard HR, Wolters PJ, Egen JG, Arron JR.

Thorax. 2017 Sep;72(9):780-787. doi: 10.1136/thoraxjnl-2015-207682. Epub 2017 Mar 1.

PMID:
28250200
43.

Pathologic Findings and Prognosis in a Large Prospective Cohort of Chronic Hypersensitivity Pneumonitis.

Wang P, Jones KD, Urisman A, Elicker BM, Urbania T, Johannson KA, Assayag D, Lee J, Wolters PJ, Collard HR, Koth LL.

Chest. 2017 Sep;152(3):502-509. doi: 10.1016/j.chest.2017.02.011. Epub 2017 Feb 20.

PMID:
28223152
44.

Reply: Acute Exacerbation of Idiopathic Pulmonary Fibrosis.

Corte TJ, Ryerson CJ, Collard HR.

Am J Respir Crit Care Med. 2017 Feb 15;195(4):542-543. doi: 10.1164/rccm.201610-2025LE. No abstract available.

PMID:
28199161
45.

Reply: The New Idiopathic Pulmonary Fibrosis Acute Exacerbations Document: One Step Ahead but Still Suspended in the Air.

Ryerson CJ, Corte TJ, Martinez FJ, Collard HR.

Am J Respir Crit Care Med. 2017 Jan 15;195(2):269. doi: 10.1164/rccm.201608-1607LE. No abstract available.

PMID:
28084823
46.

The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.

Brownell R, Moua T, Henry TS, Elicker BM, White D, Vittinghoff E, Jones KD, Urisman A, Aravena C, Johannson KA, Golden JA, King TE Jr, Wolters PJ, Collard HR, Ley B.

Thorax. 2017 May;72(5):424-429. doi: 10.1136/thoraxjnl-2016-209671. Epub 2017 Jan 12.

47.

Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.

Raghu G, Brown KK, Collard HR, Cottin V, Gibson KF, Kaner RJ, Lederer DJ, Martinez FJ, Noble PW, Song JW, Wells AU, Whelan TP, Wuyts W, Moreau E, Patterson SD, Smith V, Bayly S, Chien JW, Gong Q, Zhang JJ, O'Riordan TG.

Lancet Respir Med. 2017 Jan;5(1):22-32. doi: 10.1016/S2213-2600(16)30421-0. Epub 2016 Dec 7.

PMID:
27939076
48.

The diagnosis of idiopathic pulmonary fibrosis: current and future approaches.

Martinez FJ, Chisholm A, Collard HR, Flaherty KR, Myers J, Raghu G, Walsh SL, White ES, Richeldi L.

Lancet Respir Med. 2017 Jan;5(1):61-71. doi: 10.1016/S2213-2600(16)30325-3. Epub 2016 Dec 6. Review.

49.

Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy?

Nathan SD, Behr J, Cottin V, Collard HR, Hoeper MM, Martinez FJ, Wells AU.

Respir Med. 2017 Jan;122 Suppl 1:S10-S13. doi: 10.1016/j.rmed.2016.11.003. Epub 2016 Nov 5.

50.

Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis.

Morisset J, Johannson KA, Vittinghoff E, Aravena C, Elicker BM, Jones KD, Fell CD, Manganas H, Dubé BP, Wolters PJ, Collard HR, Ryerson CJ, Ley B.

Chest. 2017 Mar;151(3):619-625. doi: 10.1016/j.chest.2016.10.029. Epub 2016 Nov 3.

Supplemental Content

Loading ...
Support Center